{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T17:05:25Z","timestamp":1775322325099,"version":"3.50.1"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T00:00:00Z","timestamp":1571097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12,18]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Germline BRCA1 and BRCA2 mutations are the most common gene mutations in familial pancreatic adenocarcinoma. Several reports have demonstrated the utility of platinum-based chemotherapy for treating cancer patients who harbour a BRCA mutation. Here we discuss a 47-year-old Japanese female with no relevant past history who presented with epigastralgia and fever in September 2016. A computed tomography scan revealed a low-density, low-enhanced tumour 15\u00a0mm in diameter in the head of the pancreas. The pathological diagnosis was a ductal pancreatic carcinoma. A 6\u00a0mm low-enhanced metastatic tumour was also detected in segment 4 of the liver. Because she had early onset of the disease and a family history\u2014her mother died of pancreatic adenocarcinoma at age 48\u2014we considered a diagnosis of familial pancreatic adenocarcinoma. She received modified FOLFIRINOX. Two months after starting chemotherapy, she was diagnosed with an invasive ductal carcinoma in the right breast. FOLFIRINOX was continued for 8\u00a0cycles (4\u00a0months); the primary pancreatic adenocarcinoma shrank and the liver metastatic foci disappeared, but the size of the breast tumour increased. Total right breast excision and sentinel lymph node dissection were performed. FOLFIRINOX was continued and after 12\u00a0cycles (6\u00a0months), both her pancreatic adenocarcinoma and liver metastasis were no longer visible using imaging. Pancreatoduodenectomy was performed and the primary tumour had shrunk to 2.5\u00a0mm. Genetic testing revealed a germline BRCA2 mutation. The FOLFIRINOX regimen showed dramatic effects on the collision pancreatic but not on the breast cancer.<\/jats:p>","DOI":"10.1093\/jjco\/hyz141","type":"journal-article","created":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T19:28:18Z","timestamp":1567625298000},"page":"1049-1054","source":"Crossref","is-referenced-by-count":18,"title":["Dramatic response of FOLFIRINOX regimen in a collision pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report"],"prefix":"10.1093","volume":"49","author":[{"given":"Hideki","family":"Shimmura","sequence":"first","affiliation":[{"name":"Department of Internal medicine, Division of Gastroenterology, Tokyo Women\u2019s Medical University, Yachiyo Medical Center, Yachiyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidekazu","family":"Kuramochi","sequence":"additional","affiliation":[{"name":"Department of Chemotherapy, Tokyo Women\u2019s Medical University, Yachiyo Medical Center, Yachiyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norie","family":"Jibiki","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Breast and Endocrinological Surgery, Tokyo Women\u2019s Medical University, Yachiyo Medical Center, Yachiyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Katagiri","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Gastroenterological Surgery, Tokyo Women\u2019s Medical University, Yachiyo Medical Center, Yachiyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayoshi","family":"Nishino","sequence":"additional","affiliation":[{"name":"Department of Internal medicine, Division of Gastroenterology, Tokyo Women\u2019s Medical University, Yachiyo Medical Center, Yachiyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuo","family":"Araida","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Gastroenterological Surgery, Tokyo Women\u2019s Medical University, Yachiyo Medical Center, Yachiyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,10,15]]},"reference":[{"key":"2019122810174583200_ref1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mc.20855","article-title":"Genetic susceptibility to pancreatic cancer","volume":"51","author":"Klein","year":"2012","journal-title":"Mol Carcinog"},{"key":"2019122810174583200_ref2","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.hoc.2015.04.007","article-title":"Familial pancreatic adenocarcinoma","volume":"29","author":"Petersen","year":"2015","journal-title":"Hematol Oncol Clin North Am"},{"key":"2019122810174583200_ref3","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/jnci\/95.3.214","article-title":"BRCA2 germline mutations in familial pancreatic carcinoma","volume":"95","author":"Hahn","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"2019122810174583200_ref4","first-page":"149","article-title":"BRCA-associated pancreatic cancer: The evolving management","volume":"14","author":"Leung","year":"2013","journal-title":"JOP"},{"key":"2019122810174583200_ref5","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1038\/bjc.2012.483","article-title":"The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers","volume":"107","author":"Iqbal","year":"2012","journal-title":"Br J Cancer"},{"key":"2019122810174583200_ref6","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/cncr.26191","article-title":"Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer","volume":"118","author":"Stadler","year":"2012","journal-title":"Cancer"},{"key":"2019122810174583200_ref7","doi-asserted-by":"crossref","first-page":"74227","DOI":"10.18632\/oncotarget.12490","article-title":"Germline mutations in Japanese familial pancreatic cancer patients","volume":"7","author":"Takai","year":"2016","journal-title":"Oncotarget"},{"key":"2019122810174583200_ref8","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/bjc.2015.220","article-title":"BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts","volume":"113","author":"Lohse","year":"2015","journal-title":"Br J Cancer"},{"key":"2019122810174583200_ref9","doi-asserted-by":"crossref","first-page":"36033","DOI":"10.18632\/oncotarget.16422","article-title":"BRCA1 missense polymorphisms are associated with poor prognosis of pancreatic cancer patients in a Chinese population","volume":"8","author":"Zhu","year":"2017","journal-title":"Oncotarget"},{"key":"2019122810174583200_ref10","doi-asserted-by":"crossref","first-page":"e4812","DOI":"10.1371\/journal.pone.0004812","article-title":"Potential excess mortality in BRCA1\/2 mutation carriers beyond breast, ovarian, prostate, and pancreatic cancers, and melanoma","volume":"4","author":"Mai","year":"2009","journal-title":"PLoS One"},{"key":"2019122810174583200_ref11","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1038\/bjc.2014.418","article-title":"Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers","volume":"111","author":"Golan","year":"2014","journal-title":"Br J Cancer"},{"key":"2019122810174583200_ref12","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1634\/theoncologist.2011-0185","article-title":"An emerging entity: Pancreatic adenocarcinoma associated with a known BRCA mutation: Clinical descriptors, treatment implications, and future directions","volume":"16","author":"Lowery","year":"2011","journal-title":"Oncologist"},{"key":"2019122810174583200_ref13","doi-asserted-by":"crossref","first-page":"165","DOI":"10.4161\/cbt.12.3.16292","article-title":"Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy","volume":"12","author":"Sonnenblick","year":"2011","journal-title":"Cancer Biol Ther"},{"key":"2019122810174583200_ref14","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00280-015-2788-6","article-title":"Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma","volume":"76","author":"Fogelman","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"2019122810174583200_ref15","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"2019122810174583200_ref16","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s00280-018-3577-9","article-title":"A phase II study of modified FOLFIRINOX for chemotherapy-naive patients with metastatic pancreatic cancer","volume":"81","author":"Ozaka","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"2019122810174583200_ref17","doi-asserted-by":"crossref","first-page":"e0168730","DOI":"10.1371\/journal.pone.0168730","article-title":"Do patients with luminal a breast cancer profit from adjuvant systemic therapy? A retrospective multicenter study","volume":"11","author":"Diessner","year":"2016","journal-title":"PLoS One"},{"key":"2019122810174583200_ref18","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1002\/cncr.26553","article-title":"Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent","volume":"118","author":"Mayo","year":"2012","journal-title":"Cancer"},{"key":"2019122810174583200_ref19","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S1091-255X(00)80105-5","article-title":"Resected adenocarcinoma of the pancreas-616 patients: Results, outcomes, and prognostic indicators","volume":"4","author":"Sohn","year":"2000","journal-title":"J Gastrointest Surg"},{"key":"2019122810174583200_ref20","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","article-title":"Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)","volume":"388","author":"Uesaka","year":"2016","journal-title":"Lancet"},{"key":"2019122810174583200_ref21","doi-asserted-by":"crossref","first-page":"935","DOI":"10.3748\/wjg.v23.i6.935","article-title":"Familial pancreatic cancer: Concept, management and issues","volume":"23","author":"Matsubayashi","year":"2017","journal-title":"World J Gastroenterol"},{"key":"2019122810174583200_ref22","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1200\/JCO.2009.27.5719","article-title":"Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer","volume":"28","author":"Konstantinopoulos","year":"2010","journal-title":"J Clin Oncol"},{"key":"2019122810174583200_ref23","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1200\/JCO.1999.17.1.409","article-title":"Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin","volume":"17","author":"Go","year":"1999","journal-title":"J Clin Oncol"},{"key":"2019122810174583200_ref24","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1002\/cncr.11310","article-title":"Improved survival in women with BRCA-associated ovarian carcinoma","volume":"97","author":"Cass","year":"2003","journal-title":"Cancer"},{"key":"2019122810174583200_ref25","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1200\/JCO.2008.16.1703","article-title":"\u201cBRCAness\u201d syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations","volume":"26","author":"Tan","year":"2008","journal-title":"J Clin Oncol"},{"key":"2019122810174583200_ref26","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1200\/JCO.2014.57.6660","article-title":"TBCRC009: a multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer","volume":"33","author":"Isakoff","year":"2015","journal-title":"J Clin Oncol"},{"key":"2019122810174583200_ref27","doi-asserted-by":"crossref","first-page":"R110","DOI":"10.1186\/bcr3231","article-title":"Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer","volume":"14","author":"Byrski","year":"2012","journal-title":"Breast Cancer Res"},{"key":"2019122810174583200_ref28","first-page":"CD003374","article-title":"Platinum-containing regimens for metastatic breast cancer","volume":"6","author":"Egger","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2019122810174583200_ref29","doi-asserted-by":"crossref","first-page":"e111651","DOI":"10.1371\/journal.pone.0111651","article-title":"The prognostic value of excision repair cross-complementation group 1 (ERCC1) in patients with small cell lung cancer (SCLC) receiving platinum-based chemotherapy: evidence from meta-analysis","volume":"9","author":"Yang","year":"2014","journal-title":"PLoS One"},{"key":"2019122810174583200_ref30","first-page":"507","article-title":"ERCC1 expression in metastatic triple negative breast cancer patients treated with platinum-based chemotherapy","volume":"18","author":"MA","year":"2017","journal-title":"Asian Pac J Cancer Prev"},{"key":"2019122810174583200_ref31","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a Germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"key":"2019122810174583200_ref32","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"key":"2019122810174583200_ref33","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.molonc.2012.10.002","article-title":"Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity","volume":"7","author":"Porcelli","year":"2013","journal-title":"Mol Oncol"},{"key":"2019122810174583200_ref34","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s00432-018-2666-9","article-title":"Emerging strategies in BRCA-positive pancreatic cancer","volume":"144","author":"Kowalewski","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"key":"2019122810174583200_ref35","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N Engl J Med"},{"key":"2019122810174583200_ref36","author":"National Comprehensive Cancer Network"},{"key":"2019122810174583200_ref37","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/49\/11\/1049\/31630334\/hyz141.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/49\/11\/1049\/31630334\/hyz141.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T13:57:27Z","timestamp":1664287047000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/49\/11\/1049\/5587305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,15]]},"references-count":37,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,10,15]]},"published-print":{"date-parts":[[2019,12,18]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyz141","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,11]]},"published":{"date-parts":[[2019,10,15]]}}}